Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …

Of the many targeted therapies introduced since 2006, sunitinib has carved its way to
become the most commonly used first-line therapy for the treatment of metastatic renal cell …

The introduction of agents that inhibit tumor angiogenesis by targeting vascular endothelial
growth factor (VEGF) signaling has made a significant impact on the survival of patients with …

As a multitargeted kinase inhibitor, sunitinib has carved its way into demonstrating itself as a
most effective tyrosine kinase inhibitor in the treatment of metastatic renal cell carcinoma …

The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell
renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Unfortunately, most patients …

Antiangiogenic therapy resistance occurs frequently in patients with metastatic renal cell
carcinoma (RCC). The purpose of this study was to understand the mechanism of resistance …

Abstract Sunitinib malate (SU11248/Sutent; Pfizer) is a multitargeted tyrosine kinase
inhibitor that has potent anti-angiogenic and antitumour activities. Definitive efficacy has …

The oral multikinase inhibitor sunitinib malate was approved by the US Food and Drug
Administration in January 2006 for use in patients with advanced renal cell carcinoma …

Background Antiangiogenic agents that specifically target vascular endothelial growth factor
receptor (VEGFR), such as sunitinib, have been utilized as the standard therapy for …

Background Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell
carcinoma, but some patients do not respond or need dose reductions due to toxicity …